Eleven consecutive male patients with operable Stage II (n = 7) or III (n = 4) breast cancer were treated with adjuvant chemotherapy after local therapy. Adjuvant therapy consisted of 5-fluorouracil, doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and cyclophosphamide (FAC) in ten patients and cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in one patient. At a median follow-up time of 52 months, four patients experienced a relapse and seven patients were disease-free. Of those with recurrent disease, one patient died of metastatic breast cancer. These limited data suggest that adjuvant therapy reduced the risk of recurrence and favorably influenced the survival in this patient population. Adjuvant therapy should be considered in male patients with primary breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.